Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CCCC NYSEARCA:IWM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCCCCC4 Therapeutics$3.56$2.90$1.21▼$3.95$393.63M2.772.89 million shs1.71 million shsIWMiShares Russell 2000 ETF$285.12$265.43$199.65▼$287.58$79.18B1.1138.62 million shs23.79 million shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCCCCC4 Therapeutics0.00%0.00%+23.61%+54.78%+157.97%IWMiShares Russell 2000 ETF0.00%+2.71%+3.06%+9.46%+40.76%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCCCCC4 Therapeutics$3.56$2.90$1.21▼$3.95$393.63M2.772.89 million shs1.71 million shsIWMiShares Russell 2000 ETF$285.12$265.43$199.65▼$287.58$79.18B1.1138.62 million shs23.79 million shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCCCCC4 Therapeutics0.00%0.00%+23.61%+54.78%+157.97%IWMiShares Russell 2000 ETF0.00%+2.71%+3.06%+9.46%+40.76%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCCCCC4 Therapeutics 2.57Moderate Buy$7.75117.70% UpsideIWMiShares Russell 2000 ETF 2.70Moderate Buy$285.12N/ACurrent Analyst Ratings BreakdownLatest CCCC and IWM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/20/2026CCCCC4 Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)2/26/2026CCCCC4 Therapeutics BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$5.00 ➝ $7.002/26/2026CCCCC4 Therapeutics TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy(Data available from 5/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCCCCC4 Therapeutics$35.95M10.95N/AN/A$2.12 per share1.68IWMiShares Russell 2000 ETFN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCCCCC4 Therapeutics-$104.99M-$1.19N/AN/AN/A-297.76%-50.68%-33.22%8/6/2026 (Estimated)IWMiShares Russell 2000 ETFN/AN/A17.69N/AN/AN/AN/AN/AN/ALatest CCCC and IWM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026CCCCC4 Therapeutics-$0.2506-$0.20+$0.0506-$0.20$4.42 million$6.15 million2/26/2026Q4 2025CCCCC4 Therapeutics-$0.43-$0.18+$0.25-$0.18$4.48 million$11.02 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCCCCC4 TherapeuticsN/AN/AN/AN/AN/AIWMiShares Russell 2000 ETF$2.530.89%N/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCCCCC4 TherapeuticsN/A9.009.00IWMiShares Russell 2000 ETFN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCCCCC4 Therapeutics78.81%IWMiShares Russell 2000 ETFN/AInsider OwnershipCompanyInsider OwnershipCCCCC4 Therapeutics5.60%IWMiShares Russell 2000 ETFN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCCCCC4 Therapeutics150110.57 million104.38 millionOptionableIWMiShares Russell 2000 ETFN/A277.70 millionN/ANot OptionableCCCC and IWM HeadlinesRecent News About These CompaniesShould iShares Russell 2000 ETF (IWM) Be on Your Investing Radar?4 hours ago | finance.yahoo.comShould iShares Russell 2000 ETF (IWM) Be on Your Investing Radar?May 25 at 7:21 AM | zacks.comRising Rates Are Threatening to Kill the Zombies and Send Small-Cap Stocks PlungingMay 23 at 6:35 PM | barchart.comDollar Holds Firm Amid Iran Deal Uncertainty: ETFs to Win/ LoseMay 22 at 9:15 AM | zacks.comSmall caps finally woke up — now they're testing traders again: Chart of the DayMay 20, 2026 | finance.yahoo.comETF Prime: ETF Inflows on Pace to Shatter Annual RecordMay 20, 2026 | etftrends.comEThe Russell 2000 Is Up 31% and These 2 Small Cap Stocks Under $30 Have the Fundamentals to Keep RunningMay 19, 2026 | 247wallst.comThe New Federal Reserve Chair Can Cause This Small-Cap Stock ETF to SurgeMay 18, 2026 | 247wallst.comSmall-Cap ETFs May Be Prepping For A Comeback Investors Are Still Ignoring: Here Are Four You Can Start WithMay 18, 2026 | benzinga.comThe New Federal Reserve Chair Can Cause This Small-Cap Stock ETF to SurgeMay 18, 2026 | 247wallst.comExchange-Traded Funds, Equity Futures Lower Pre-Bell Monday Amid Stalled Iran Peace Efforts, Inflation ConcernsMay 18, 2026 | finance.yahoo.comWhy DES Monthly Dividends Look Safer Than They Actually AreMay 18, 2026 | 247wallst.comMacro Indicators at a Crossroads. Charts of Dow Industrials, Small Caps, 10-Year Yield Tell the Story.May 15, 2026 | finance.yahoo.comThe Battle of iShares ETFs: Should You Buy the S&P 500 ETF or Russell 2000?May 14, 2026 | fool.comIWM and VTWO Track the Same 2000 Stocks Yet VTWO's Ten-Year Return Crushes IWM by Nearly 40 Percentage PointsMay 14, 2026 | 247wallst.comNavigating the Small-Cap ETF DisconnectMay 13, 2026 | etftrends.comEHow We Leveraged Our Position In Russell 2000 For A WinMay 8, 2026 | finance.yahoo.comWhich Is the Better Growth ETF, the Vanguard Mega Cap Growth ETF or iShares Russell 2000 ETF?May 8, 2026 | fool.comETF Fund Flows as of May 5, 2026May 6, 2026 | etf.comEExchange-Traded Funds, Equity Futures Higher Pre-Bell Wednesday Amid Potential US-Iran TruceMay 6, 2026 | finance.yahoo.comRussell 2000 Tracking for New Highs: What’s Next for ETF Traders?...April 13, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCCCC and IWM Company DescriptionsC4 Therapeutics NASDAQ:CCCC$3.56 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$3.55 -0.01 (-0.25%) As of 05/22/2026 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.iShares Russell 2000 ETF NYSEARCA:IWM$285.12 0.00 (0.00%) As of 05/22/2026 04:10 PM EasterniShares Russell 2000 ETF (the Fund) is an exchange-traded fund. The Fund seeks investment results that correspond generally to the price and yield performance of the Russell 2000 Index (the Index). The Index is a float-adjusted capitalization weighted index that measures the performance of the small-capitalization sector of the United States equity market and includes securities issued by the approximately 2,000 smallest issuers in the Russell 3000 Index. The Fund invests in a representative sample of securities included in the Index that collectively has an investment profile similar to the Index. The Index is a subset of the Russell 3000 Index, and serves as the underlying index for the Russell 2000 Growth and Value Index series. Component companies are adjusted for available float and must meet objective criteria for inclusion to the Index. The Fund's investment adviser is BlackRock Fund Advisors (BFA). More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/18 - 05/22 Ross Stores Earnings Beat Sends Stock To New Highs Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus? Workday Validates AI Flywheel: Stock Price Recovery Begins Apparel Earnings Winners and Losers: Ralph Lauren Takes Off SpaceX IPO: Opportunity? Or the Ultimate Hype Trade? The Careful Consumer: What Q1 Earnings Reveal—And Where Cracks May Appear Overextended, e.l.f. Beauty Is Primed to Rebound in Back Half Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
